Norovirus Infection Can Occur in Emtuzumab Treatment

by / 0 Comments / 19 View / December 14, 2014

Norovirus-related chronic diarrhea in a patient treated with alemtuzumab for chronic lymphocytic leukemia

Norovirus infection is increasingly recognized as an important cause of persistent gastroenteritis in immunocompromised hosts and can be a  potential cause of morbidity in these populations.
Case presentation:
Here, we report a case of norovirus-related chronic diarrhea occurring in a 62-year-old immunocompromised patient treated with  alemtuzumab for chronic lymphocytic leukemia. Despite different therapeutic strategies including tapering of immunosuppressive therapy and  immunoglobulin administration, diarrhea unfortunately did not resolve and lasted for a total of more than twelve weeks with prolonged  norovirus fecal excretion.
Norovirus infection can occur in the setting of alemtuzumab treatment, even as a single agent, and should be included in the differential  diagnoses of acute and chronic diarrhea in these immunocompromised patients. Although the administration of oral immunoglobulin has been  described as a promising efficient therapy, this was not the case in our patient. Clinical trials are thus clearly warranted to better define risk  factors and efficient therapies for norovirus infection in immunocompromised populations.

Your Commment

Email (will not be published)